219 related articles for article (PubMed ID: 34627003)
1. Impact of COVID-19 public health measures on myelin oligodendrocyte glycoprotein IgG-associated disorders in children.
Kaseka ML; Ly M; Yea C; Longoni G; Yeh EA
Mult Scler Relat Disord; 2021 Nov; 56():103286. PubMed ID: 34627003
[TBL] [Abstract][Full Text] [Related]
2. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
3. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
4. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
[TBL] [Abstract][Full Text] [Related]
5. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.
Dinoto A; Sechi E; Ferrari S; Gajofatto A; Orlandi R; Solla P; Maccabeo A; Maniscalco GT; Andreone V; Sartori A; Manganotti P; Rasia S; Capra R; Mancinelli CR; Mariotto S
Mult Scler Relat Disord; 2022 Feb; 58():103424. PubMed ID: 35216793
[TBL] [Abstract][Full Text] [Related]
6. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
8. Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis.
Chia NH; Redenbaugh V; Chen JJ; Pittock SJ; Flanagan EP
Mult Scler; 2023 May; 29(6):748-752. PubMed ID: 36691800
[TBL] [Abstract][Full Text] [Related]
9. Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
Gernert JA; Wicklein R; Hemmer B; Kümpfel T; Knier B; Havla J
J Neurol; 2023 Feb; 270(2):1135-1140. PubMed ID: 36245037
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
11. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
12. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.
Sharma J; Bhatti MT; Danesh-Meyer HV
Clin Exp Ophthalmol; 2021 Mar; 49(2):186-202. PubMed ID: 33426799
[TBL] [Abstract][Full Text] [Related]
14. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
[TBL] [Abstract][Full Text] [Related]
17. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
Lin L; Wu Y; Hang H; Lu J; Ding Y
Front Immunol; 2022; 13():853891. PubMed ID: 35898513
[TBL] [Abstract][Full Text] [Related]
18. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
[No Abstract] [Full Text] [Related]
20. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
[Next] [New Search]
